MedTrace Logo

To Develop Methods for the Rehabilitation of Chronic Gastroduodenal Pathology in Children.

NCT04702542 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2025-05-21

No results posted yet for this study

Summary

The object of the study will be children and adolescents from 6 to 15 years old, living in the city of Tashkent and in the Tashkent region. We will study patients with various clinical forms of chronic gastroduodenal pathology (CGDP). The effect of enteral oxygen therapy in the recovery of patients with CGDP due to the positive effect of the active form of oxygen on the hematological system and on the regenerative processes in the gastrointestinal tract will be studied. At the same time, the effect of enteral oxygen therapy on enhancing the effectiveness of eradication therapy during the treatment of carrier Helicobacter pylori due to the neutralization of the products of urea hydrolysis around bacteria under the action of reactive oxygen species will be studied.

Conditions

  • Gastritis Chronic
  • Gastroduodenitis
  • Peptic Ulcer
  • Duodenal Ulcer

Interventions

DRUG

Enteral oxygen therapy

Enteral oxygen therapy during the rehabilitation period of patients with CGDP.

Sponsors & Collaborators

  • Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan

    lead OTHER

Principal Investigators

  • Shokhida Turdieva, MD · Tashkent State Medical University (Tashkent Pediatric Medical Institute), Uzbekistan

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
15 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-30
Primary Completion
2025-12-30
Completion
2028-12-30

Countries

  • Uzbekistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04702542 on ClinicalTrials.gov